NCT01021488

Rosuvastatin for Preventing Deep Vein Thrombosis

Rosuvastatin for Prevention of Deep Vein Thrombosis in Patients Undergoing Total Knee Replacement Arthroplasty: STOP DVT - A Prospective Randomized Controlled Trial

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Hallym University Medical Center · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Deep vein thrombosis (DVT)is devastating disease which influencing the mortality and morbidity of patients at-risk like those undergoing orthopedic surgery. Recent publication suggested HMO-co-A reductase inhibitor (statin) may reduce the occurrence rate of venous thromboembolism in apparently healthy persons. The pleiotropic property of statin like antioxidant, antithrombotic, anti-inflammatory may have effect on the positive results. We are investigating whether rosuvastatin is associated with lower incidence of deep vein thrombosis (DVT) in patients undergoing total knee replacement arthroplasty(TKRA)who are at-high risk for developing DVT

Conditions

• Deep Vein Thrombosis
• Venous
• Thrombosis
• Prevention

Interventions

Type	Name	Description
DRUG	Rosuvastatin 20mg/d for 14days	Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
DRUG	enoxaparin only	enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery

Timeline

• Start date: 2009-10-01
• Primary completion: 2011-12-01
• Completion: 2012-03-01
• First posted: 2009-11-30
• Last updated: 2011-10-05

Locations

1 site across 1 country: South Korea